Blueprint Medicines Co. (NASDAQ:BPMC) Receives $122.11 Average PT from Brokerages

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have been given an average rating of “Moderate Buy” by the twenty-one brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $122.11.

A number of research analysts recently commented on BPMC shares. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Needham & Company LLC reiterated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, November 15th. JMP Securities restated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Monday, December 9th. Wells Fargo & Company dropped their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. began coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 target price on the stock.

Insider Buying and Selling

In other Blueprint Medicines news, CEO Kate Haviland sold 2,353 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $96.60, for a total value of $227,299.80. Following the sale, the chief executive officer now owns 150,824 shares in the company, valued at approximately $14,569,598.40. This represents a 1.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Ariel Hurley sold 1,819 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the sale, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,079 shares of company stock valued at $937,697 over the last quarter. 4.21% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Amalgamated Bank lifted its stake in shares of Blueprint Medicines by 5.3% in the second quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock worth $232,000 after buying an additional 109 shares in the last quarter. Van ECK Associates Corp lifted its stake in Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $120,000 after purchasing an additional 131 shares in the last quarter. EFG Asset Management North America Corp. boosted its holdings in shares of Blueprint Medicines by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock worth $3,008,000 after purchasing an additional 132 shares during the last quarter. Pallas Capital Advisors LLC grew its position in shares of Blueprint Medicines by 3.2% in the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 176 shares in the last quarter. Finally, Clarus Wealth Advisors increased its holdings in shares of Blueprint Medicines by 8.6% in the third quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 206 shares during the last quarter.

Blueprint Medicines Trading Up 1.1 %

Shares of Blueprint Medicines stock opened at $96.48 on Wednesday. The firm has a market cap of $6.13 billion, a price-to-earnings ratio of -45.73 and a beta of 0.59. The business has a 50-day moving average price of $92.33 and a 200-day moving average price of $97.32. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. Blueprint Medicines has a twelve month low of $72.24 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. Blueprint Medicines’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same period last year, the firm posted ($2.20) earnings per share. Equities research analysts anticipate that Blueprint Medicines will post -3.68 EPS for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.